A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles
Source abstract
Abstract
Abstract Efficient and precise delivery of mRNA is critical to advance mRNA therapies beyond their current use as vaccines. Lipid nanoparticles (LNPs) efficiently encapsulate and protect mRNA, but non-specific cellular uptake may lead to off-target delivery and minimal delivery to target cells. Functionalizing LNPs with antibodies enables targeted mRNA delivery, but traditional modification techniques require complex conjugation and purification, which often reduces antibody affinity. Here we present a simple method for capturing antibodies in their optimal orientation on LNPs, without antibody modification or complex purification. This strategy uses an optimally oriented anti-Fc nanobody on the LNP surface to capture antibodies, resulting in protein expression levels more than 1,000 times higher than non-targeted LNPs and more than 8 times higher than conventional antibody functionalization techniques. These precisely targeted LNPs showed highly efficient in vivo targeting to T cells, with minimal delivery to other immune cells. This approach enables the rapid development of targeted LNPs and has the potential to broaden the use of mRNA therapies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Monoclonal and Polyclonal Antibodies Research · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target Ther. 7, 166 (2022).10.1038/s41392-022-01007-w ↗
2. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).10.1056/NEJMoa2034577 ↗
3. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).10.1056/NEJMoa2035389 ↗
4. Kim, M. et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv. 7, eabf4398 (2021).10.1126/sciadv.abf4398 ↗
5. Naidu, G. S. et al. A combinatorial library of lipid nanoparticles for cell type-specific mRNA delivery. Adv. Sci. 10, e2301929 (2023).10.1002/advs.202301929 ↗
6. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).10.1038/s41565-020-0669-6 ↗
7. Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 41, 1410–1415 (2023).10.1038/s41587-023-01679-x ↗
8. Veiga, N. et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat. Commun. 9, 4493 (2018).10.1038/s41467-018-06936-1 ↗
9. Singh, M. S. et al. Therapeutic gene silencing using targeted lipid nanoparticles in metastatic ovarian cancer. Small 17, e2100287 (2021).10.1002/smll.202100287 ↗
10. Tarab-Ravski, D. et al. Delivery of therapeutic RNA to the bone marrow in multiple myeloma using CD38-targeted lipid nanoparticles. Adv. Sci. 10, e2301377 (2023).10.1002/advs.202301377 ↗
11. Su, F. Y. et al. In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. Sci. Adv. 8, eabm7950 (2022).10.1126/sciadv.abm7950 ↗
12. Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91–96 (2022).10.1126/science.abm0594 ↗
13. Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436–443 (2023).10.1126/science.ade6967 ↗
14. Kang, J. H. et al. Improving immunobinding using oriented immobilization of an oxidized antibody. J. Chromatogr. A 1161, 9–14 (2007).10.1016/j.chroma.2007.05.023 ↗
15. Vashist, S. K. et al. Effect of antibody immobilization strategies on the analytical performance of a surface plasmon resonance-based immunoassay. Analyst 136, 4431–4436 (2011).10.1039/c1an15325k ↗
16. Spicer, C. D. & Davis, B. G. Selective chemical protein modification. Nat. Commun. 5, 4740 (2014).10.1038/ncomms5740 ↗
17. Nuhn, L. et al. Targeting protumoral tumor-associated macrophages with nanobody-functionalized nanogels through strain promoted azide alkyne cycloaddition ligation. Bioconjug. Chem. 29, 2394–2405 (2018).10.1021/acs.bioconjchem.8b00319 ↗
18. Kedmi, R. et al. A modular platform for targeted RNAi therapeutics. Nat. Nanotechnol. 13, 214–219 (2018).10.1038/s41565-017-0043-5 ↗
19. Veiga, N. et al. Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target. J. Control. Release 313, 33–41 (2019).10.1016/j.jconrel.2019.10.001 ↗
20. Dammes, N. et al. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nat. Nanotechnol. 16, 1030–1038 (2021).10.1038/s41565-021-00928-x ↗
21. Budisa, N. Prolegomena to future experimental efforts on genetic code engineering by expanding its amino acid repertoire. Angew. Chem. Int. Ed. 43, 6426–6463 (2004).10.1002/anie.200300646 ↗
22. Yong, K. W. et al. Pointing in the right direction: controlling the orientation of proteins on nanoparticles improves targeting efficiency. Nano Lett. 19, 1827–1831 (2019).10.1021/acs.nanolett.8b04916 ↗
23. Pleiner, T., Bates, M. & Gorlich, D. A toolbox of anti-mouse and anti-rabbit IgG secondary nanobodies. J. Cell Biol. 217, 1143–1154 (2018).10.1083/jcb.201709115 ↗
24. Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).10.7554/eLife.42166 ↗
25. Chin, J. W. et al. Addition of p-azido-l-phenylalanine to the genetic code of Escherichia coli. J. Am. Chem. Soc. 124, 9026–9027 (2002).10.1021/ja027007w ↗
26. Mukai, T. et al. Highly reproductive Escherichia coli cells with no specific assignment to the UAG codon. Sci. Rep. 5, 9699 (2015).10.1038/srep09699 ↗
27. Liu, H. et al. Beyond the endosomal bottleneck: understanding the efficiency of mRNA/LNP delivery. Adv. Funct. Mater. 34, 2404510 (2024).10.1002/adfm.202404510 ↗
28. Zhang, Y. et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J. 13, 61 (2023).10.1038/s41408-023-00822-w ↗
29. Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32, 995–1007 (2022).10.1038/s41422-022-00721-y ↗
30. Dai, Z. et al. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct. Target. Ther. 7, 85 (2022).10.1038/s41392-022-00898-z ↗
31. Alcover, A. & Alarcón, B. Internalization and intracellular fate of TCR-CD3 complexes. Crit. Rev. Immunol. 20, 325–346 (2000).10.1615/CritRevImmunol.v20.i4.20 ↗
32. Rennick, J. J., Johnston, A. P. R. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266–276 (2021).10.1038/s41565-021-00858-8 ↗
33. Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561–569 (2008).10.1038/nbt1402 ↗
34. O’Reilly, M. K., Tian, H. & Paulson, J. C. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J. Immunol. 186, 1554–1563 (2011).10.4049/jimmunol.1003005 ↗
35. Du, X. et al. Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 68, 6300–6305 (2008).10.1158/0008-5472.CAN-08-0461 ↗
36. Menon, A. P. et al. Modulating T cell responses by targeting CD3. Cancers 15, 1189 (2023).10.3390/cancers15041189 ↗
37. Martin, G. H. et al. Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model. Front Immunol. 15, 1357716 (2024).10.3389/fimmu.2024.1357716 ↗
38. Rosenblum, D. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 6, eabc9450 (2020).10.1126/sciadv.abc9450 ↗
39. Chen, S. et al. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J. Control. Release 235, 236–244 (2016).10.1016/j.jconrel.2016.05.059 ↗
40. Billingsley, M. M. et al. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 20, 1578–1589 (2020).10.1021/acs.nanolett.9b04246 ↗
41. Billingsley, M. M. et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533–542 (2021).10.1021/acs.nanolett.1c02503 ↗
42. Baiersdörfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).10.1016/j.omtn.2019.02.018 ↗
43. Punjani, A. et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).10.1038/nmeth.4169 ↗
44. Harris, L. J., Skaletsky, E. & McPherson, A. Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 275, 861–872 (1998).10.1006/jmbi.1997.1508 ↗
45. Goddard, T. D., Huang, C. C. & Ferrin, T. E. Visualizing density maps with UCSF Chimera. J. Struct. Biol. 157, 281–287 (2007).10.1016/j.jsb.2006.06.010 ↗
46. Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).10.1002/pro.4792 ↗
47. Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Cryst. D74, 519–530 (2018).
48. Honorato, R. V. et al. Structural biology in the clouds: the WeNMR-EOSC ecosystem. Front Mol. Biosci. 8, 729513 (2021).10.3389/fmolb.2021.729513 ↗